News & Press Releases

 

Retinal Physician January/February 2024 image
Ophthalmology Retina November, 2023, Volume 7, Number 11 image
Retina Today April 2023, Vol 18, No 3 image
Ophthalmology Retina July 2022, Volume 6, Number 7 image
Ophthalmology Science March 2022 image
New Retinal Physician November/December 2021 image
Ophthalmic Professional September 2021 image
Optometric Management August 2021 image
Ophthalmology August 2021 - Volume 128, Issue 8 image
Retinal Physician June, 2021 image
Mivision June 2021 - Issue 168 image
Review of Ophthalmology May 2021 image
Optometric Management May 2021 image
New Retinal Physician May 2021 image
Review of Optometry February 2021 image
Ophthalmology Retina February 2021, Volume 5 Issue 2 image
Retinal Physician November/December 2020 image
Ophthalmology Retina November 2020, Volume 4, Issue 11 image
Retinal Physician October 2020 image
Retinal Physician September 2020 image
Ophthalmology Retina August 2020 image
Equipment Magazine June 2020 image
Optometric Management May 2020, Volume 55, No. 5 image
Retinal Physician January/February 2020 image
Ophthalmology Retina Volume 4, Number 1 January 2020 image
Retina Specialist Volume 5, Number 6 - November/December 2019 image
OSLI Retina Volume 50, Number 8 image
Ophthalmology Retina Volume 3, Number 9, August 2019 image
Ophthalmology Management July 2019 image
Retinal Physician July/August 2019 image
Review of Optometry June 2019 image
Ophthalmology Retina Volume 3, Number 6 – June 2019 image
Canadian Journal of Ophthalmology Volume 54, Issue 2 image
Retina Today Volume 14, No. 3, April 2019 image
Clinical and Experimental Optometry March 2019 Volume 102 Number 2 image
Ophthalmology Retina Volume 3, Issue 1, January 2019 image
Canadian Journal of Ophthalmology December 2018 image
Retinal Physician September 2018 image
Ophthalmology Retina Volume 2, Issue 11, November 2018 image
Journal of VitreoRetinal Diseases July/August 2018 image
Canadian Journal of Ophthalmology August 2018 image
Retinal Physician July/August 2018 image
Retinal Physician  May 2018 image
Retinal Physician April 2018 image
Ophthalmology Retina Volume 2, Issue 3, March 2018 image
Ophthalmology Volume 1235, Number 2, February 2018 image
Canadian Journal of Ophthalmology Volume 52, Number 6, December 2017 image
Canadian Journal of Optometry Volume 79, Supplement 2, 2017 image
Ophthalmology Retina Volume 1, Number 6, November/December 2017 image
Ophthalmology Retina Volume 1, Number 4, July/August 2017 image
Ophthalmology Volume 124, Number 7, July 2017 image
Retinal Specialist June 2017 image
Ophthalmology Retina Volume 1, Issue 2, March/April 2017 image
Ophthalmology Retina Volume 1, Number 1, January/February 2017 image
OSLI Retina December 2016 image
Retinal Physician November/December 2016 image
Ophthalmology November/December 2016 image
Retinal Physician March 2016 image
Retina Specialist March 2016 image
Retina Today DME Supplement, January/February 2016 image
Optometric Office January 2016 image
New Zealand Optics November 2015 image
Review of Optometry November 2015 image
Review of Optometry May 2015 image
Retinal Physician April 2015 image
Ophthalmology Retina September 2022, Volume 6, Number 9 image
footer divots
Click an image to view details
footer divots
Tap an image to view details

 

Press releases, select articles, peer-reviewed papers, and key clinical findings. Listed chronologicially by year.

2025

Largest Reference Database
3/5/2025

Optos Announces Largest U.S. Reference Database for Ultra-widefield and OCT Imaging

Optos Unveils MonacoPro
2/14/2025

Optos Unveils MonacoPro: The Next Generation in Integrated Ultra-widefield and OCT Retinal Imaging 

Optos Celebrates Key Milestones: 25,000 Devices Installed Globally and Extensive Clinical Publications Achieved
2/26/2024

2,500 clinical and peer-reviewed studies reached which span 235 disease states, demonstrating the clinical utility of Optos technology.

Optos showcases cutting-edge Retinal Imaging Technology at 23rd EURETINA congress
10/16/2023

Optos, Plc, the leading retinal imaging company, today announces the advances of Ultra-widefield Multimodal Retinal Imaging, a central focus of Optos’ satellite symposia at EURETINA 2023.

Optos announces new Ultra-widefield color image modality, providing additional retinal visualization to eyecare professionals
5/30/2023

Optos, Plc, the leading retinal imaging company, today announces, it is expanding the optomap® ultra-widefield (UWF™) retinal imaging modalities available with the California FA device to further assist Eyecare Professionals in disease management and treatment planning.

Leading Scottish eye imaging company Optos reports significant growth with 22,000 devices installed globally – just in time for its 30th anniversary
9/27/2022

Optos, a Fife-based company, has reported significant growth with record group revenue of $254m in the year to March 22 and more than 22,000 devices installed worldwide. 

Product Announcement: Optos AI for DR
4/19/2022

Optos Plc, Unveils the First AI-based Solution for the Detection of Diabetic Retinopathy using optomap® Ultra-widefield Retinal Imaging 

 

Next Generation Daytona
12/15/2020
Optos wins Artificial Intelligence in Health and Care Award to support the early detection of diabetes in NHS patients
9/7/2020

Optos, a Fife based company and a world-leader in the design and manufacturing of advanced retinal imaging technology, has been awarded NHS funding to accelerate the implementation and validation of Artificial Intelligence (AI) to support the early detection of Diabetes related eye-disease into NHS Diabetic Eye Screening practices.

Optos Cares About Our Customers
3/19/2020
Clearing Up The Language of Retinal Imaging
11/16/2019

A review of the International Widefield Imaging Study Group recommendations for a terminology to describe image captures from various modalities.

Optos plc, Unveils Silverstone, a Combined Ultra-widefield Retinal Imaging Device and UWF-Guided Swept Source OCT for the Ophthalmic Market
10/12/2019

Optos plc, the leading medical retinal imaging company, part of Nikon Corporation, is pleased to announce the launch of Silverstone at the American Academy of Ophthalmology, San Francisco, CA.

2019 Queen's Award for Enterprise Innovation
4/23/2019

Optos business’ mission to save eyesight is recognised by Queen’s Awards

Clinical Applicability of Assessing Peripheral Nonperfusion on Ultra-Widefield Angiography: Predicting Proliferative Diabetic Retinopathy
4/16/2019

Given the well-documented relationship between posterior pole nonperfusion and DR progression, it is logical that greater peripheral nonperfusion on ultra-widefield fluorescein angiography is also associated with higher likelihood of PDR.

Eyes on the prize: Optos wins for second year running at UK optical awards
Eyes on the prize: Optos wins for second year running at UK optical awards
4/16/2019

Dunfermline-based Optos, a leading provider of retinal imaging devices, kept its crown at this year’s Optician Awards in Birmingham (30th March), claiming the title of Optical Supplier of the Year for the second time in a row.

Expanding the role of medical retina virtual clinics using multimodal ultra-widefield and optical coherence tomography imaging
Expanding the role of medical retina virtual clinics using multimodal ultra-widefield and optical coherence tomography imaging
12/1/2018

Expanding the role of medical retina virtual clinics using multimodal ultra-widefield and optical coherence tomography imaging

New Ultra-widefield Angiographic Grading Scheme for Radiation Retinopathy after Iodine-125 Bracytherapy for Uveal Melanoma
New Ultra-widefield Angiographic Grading Scheme for Radiation Retinopathy after Iodine-125 Bracytherapy for Uveal Melanoma
11/29/2018

Ultra-widefield fluorescein angiography revealed distinct fundus-wide patterns of vascular damage, which were progressive in nature in eyes treated with iodine-125 brachytherapy for uveal melanoma and correlated with signs of progressive vascular injury. This grading scheme may have prognostic value to predict the progression of radiation retinopathy and to prognosticate visual outcomes in patients undergoing brachytherapy.

Going Ultra-wide
Going Ultra-wide
10/31/2018

optomap UWF technology from Optos, is the only technology that can image beyond the vortex ampullae (up to 200° or 82% of the retina) in a single capture. optomap is available on all of our devices in all modalities and with Monaco, it can be paired with integrated spectral-domain OCT. 

New High-Tech Eye Exam Helps Doctors Detect Serious Health Issues Much Sooner — Even Breast Cancer
10/26/2018

There's new eye equipment that makes finding potential vision problems easier and more. The first advantage with this device is that it eliminates the need for your eyes to be dilated when doctors look for things like glaucoma and cataracts and it's also helping doctors detect serious health issues.

Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease
10/24/2018

Optos Plc, a subsidiary of Nikon Corporation, Japan, and Amydis, Inc. today announced a clinical alliance focused on the development of an eye test by Amydis to detect Alzheimer’s disease.  Amydis has developed a pipeline of compounds to detect amyloid proteins in the retina to be visualized with Optos’ market-leading optomap ultra-widefield retinal imaging devices to diagnose Alzheimer’s Disease in patients.  

Catching Eye Disease Associated with Diabetes
8/7/2018
UWF imaging could help to monitor disease progression in patients with Alzheimers
UWF imaging could help to monitor disease progression in patients with Alzheimers
6/27/2018

Researchers from Queen’s University Belfast have shown for the first time that the eye could be a surrogate for brain degeneration like Alzheimer’s disease (AD).

These research results have recently been published in the Journal of Ophthalmic Research and is the first clinical study showing a potential for peripheral retinal imaging to be used in monitoring AD and potentially other neurodegenerative diseases.

The team, led by Dr Imre Lengyel, Senior Lecturer and Researcher at the School of Medicine Dentistry and Biomedical Sciences at Queen’s University have found that by examining the eye we might be able to reflect on what might be taking place in the brain.

The work was carried out alongside health professionals and care providers for AD patients and explored whether there are manifestations of AD in the eye.

Based on laboratory observations the team hypothesized that changes in the peripheral retina could be important to explore the association between the eye and the brain.

Using ultra-widefield imaging technology developed by Optos Plc, the team found that there are indeed several changes that seem to be, especially in the peripheral retina, associated with this debilitating condition.

The utility of ultra-widefield fluorescein angiography in pediatric retinal diseases
6/11/2018

Ultra-widefield angiography has been successfully used without sedation for evaluation of children with various pediatric retinal diseases such as Coats disease, familial exudative vitreoretinopathy, and retinopathy of prematurity. 

Roadshow educates on the importance of regular eye exams
Roadshow educates on the importance of regular eye exams
5/14/2018

Today, Monday 14th May 2018, Optos are joining BBGR (Nikon Lenswear France)* for their annual Vision Van – the ‘Tour de France’ to highlight the importance of regular eye tests to maintain good vision. The Vision Van is an optometry practice on wheels fully equipped with an Optos Daytona plus and full eye testing equipment. The van will provide free eye tests for local communities in six towns and cities across France to educate visitors the importance of regular, thorough eye health checks.

Optos plc, a Nikon company, unveils Monaco, its next generation ultra-widefield imaging device with OCT capabilities for the U.S. ophthalmic market
5/3/2018

Optos plc, the leading medical retinal imaging company, part of Nikon Corporation, is pleased to announce that Monaco, the first ultra-widefield (UWF) imaging device combined with OCT, was launched today in the United States.

Optos crowned Optical Supplier of The Year
Optos crowned Optical Supplier of The Year
4/27/2018

As a world leading manufacturer of retinal imaging technology, Optos was crowned Optical Supplier of the Year at the Optician Awards 2018 in Birmingham on Saturday 14th April. The awards are recognised as the benchmark of excellence in the UK optical community and showcase the best in achievement, ability and performance.

Peripheral Changes Associated with Delayed Dark Adaptation in Age-related Macular Degeneration
4/10/2018

Results suggest an association between Dark Adaptation and the presence of peripheral reticular pigmentary changes, as well as the presence of a peripheral mottled decreased FAF pattern. This provides new insights on the clinical significance of peripheral changes in AMD, and their contribution to impairments on Dark Adaptation.

Peripheral Retinal Imaging Biomarkers for Alzheimer’s Disease: A Pilot Study
4/10/2018

UWF retinal imaging revealed a significant association between AD and peripheral hard drusen formation and changes to the vasculature beyond the posterior pole, at BL and
after clinical progression over 2 years, suggesting that monitoring pathological changes in the peripheral retina might become a valuable tool in AD monitoring.

Optos and prominent optomap® users shortlisted for The Optician Awards
4/5/2018

After being among the finalists for ‘Product of the Year’ for Daytona plus at the 2018 AOP Awards, we are pleased to announce that Optos has been shortlisted as ‘2018 Optical Supplier of the Year’ at the upcoming Optician Awards, “the benchmark of excellence in the Optical community” (theopticianawards.co.uk).

This year’s awards are even more exciting for Optos as we learn that a range of our UK customers have also made the finals across several categories.

Ophthalmology Retina - A Prospective Randomized Comparative Dosing Trial of Ranibizumab in Bevacizumab-Resistant Diabetic Macular Edema
3/5/2018

After conversion to ranibizumab (from bevacizumab) in eyes with persistent DME refractory to bevacizumab, significant functional and anatomic improvements were noted.  Qualitative analysis of ultra-widefield fluorescein angiography images was performed to identify retinal vascular pathologic features, specifically by observing the presence of vascular leakage, neovascularization, macular ischemia, and peripheral ischemia.  The prevalence of macular ischemia was 33.3% at baseline and remained stable at study completion. Finally, the proportion of peripheral ischemia observed in participants increased from 66.7% at baseline to 70.3% at month 12, although the incidence of any leakage remained stable at month 12.

UWF Imaging Contributes to Earlier Disease Detection
UWF Imaging Contributes to Earlier Disease Detection
2/7/2018

UWF Imaging Contributes to Earlier Disease Detection - New research confirms agreement with 7 standard field imaging 

Retina - Utility of Ultra-widefield Retinal Imaging for the Staging and Management of Sickle Cell Retinopathy
1/30/2018

Prospective, observational study including patients with sickle cell disease. All patients underwent dilated fundus examination by a fellowship-trained retina specialist, as well as UWF fundus photography (FF) and fluorescein angiography (FA). Sickle retinopathy stage and treatment recommendation per eye were determined after clinical examination, UWF-FF, and UWF-FA, respectively, and differences in retinopathy stage and treatment recommendation were compared.

Conclusion: Ultra-widefield imaging detects a higher stage of sickle cell retinopathy compared with clinical examination alone, but these differences may not be clinically significant.

AJO - Pericentral Hydroxychloroquine Retinopathy in a Caucasian Female
1/9/2018

The patient presented with 20 years of exposure to HCQ, at a daily dose of 5.2mg/kg of actual body weight, and manifested a pericentral-only phenotype of HCQ toxicity, as demonstrated with detailed structural and functional testing.

BMC Ophthalmology - The application of wide-field laser ophthalmoscopy in fundus examination before myopic refractive surgery
12/18/2017

optomap examinations are a convenient and feasible method to determine fundus pathological changes in myopic patients, especially for patients who can not endure pupil dilation. Compared to the Goldmann three-mirror contact lens examination, the detection rate with optomap was 91.73%% for retinal lesions, while the detection rate of mydriatic slit-lamp lens exams was 81.20%.

OSLI - Non-Mydriatic Ultra-Widefield Imaging Compared With Single-Field Imaging in the Evaluation of Peripheral Retinal Pathology
12/18/2017

In a primary health care clinic, 632 healthy subjects underwent UWF imaging during annual health screening.  optomap images detected peripheral retinal pathology in 18.4% that was not visible on corresponding single-field (45°) images.  UWF imaging is feasible in a primary care setting, allows improved visualization of peripheral retinal pathology, and may therefore be useful for telemedicine screening.

AJO - Peripheral pigmented retinal lesions in Stargardt disease
12/11/2017

Wide-field retinal imaging revealed the presence of peripheral pigmented retinal lesions resembling CHRPE lesions in a subset of patients with genetically confirmed Stargardt disease. Presence of these lesions may be associated with severe phenotypes of the disease.

Clinical Ophthalmology - Telemedicine for diabetic retinopathy screening using an ultra-widefield fundus camera
11/15/2017

The present study (1,024 subjects) has shown the effectiveness of DR screening using UWF fundus camera detecting 9.27% of patients with DR. It has also shown the effectiveness of trained nursing personnel taking fundus pictures. First, UWF imaging has a fast learning curve and it is quick to take the picture. Second, widefield view is greater than the 7-field photography enabling more DR lesions to be detected. And third, images can be manipulated in terms of red-free, infra-red and image zoom. Hence, the present telemedicine model has demonstrated that in a multi-specialty private hospital, DR screening can be effective using UWF fundus camera.

Ocular Immunology and Inflammation - The Impact and Implication of Peripheral Vascular Leakage in UWFFA in Uveitis
11/15/2017

Peripheral vascular leakage (PVL) is a possible independent driver of treatment augmentation. Patients with PVL were four-times more likely to have treatment augmented after adjusting for baseline presence of CME, diffuse vascular leakage and clinical grading of uveitis activity. This suggests that PVL may have influenced the decision to augment therapy in patients.

Ocular Immunology and Inflammation - Ultra-Widefield Fluorescein Angiography in Intermediate Uveitis
11/15/2017

UWFFA identifies retinal vascular pathology in intermediate uveitis not present on clinical examination. Diffuse retinal vascular leakage was associated with worse visual acuity when compared to peripheral and no leakage patterns.

Ophthalmic Epidemiology - Can ultra-wide field retinal imaging replace colour digital stereoscopy for glaucoma detection?
11/15/2017

Grading of UWF imaging has high reproducibility in evaluating vertical cup-to-disc ratio and agreement with stereoscopic optic disc imaging and may be suitable for glaucoma diagnosis in situations where colour digital stereoscopy is not available.

Ophthalmology Retina - Morphological and Angiographic Peripheral Retinal Changes in Patients with Age-Related Macular Degeneration
11/15/2017

Peripheral retinal changes were observed peripheral to the equator in more than 40% of analyzed eyes in patients with and without AMD. Drusen, reticular pigmentary change and paving stone degeneration occur significantly more frequently in eyes with AMD compared to healthy eyes. 

Optos, plc – 25 years of saving sight and saving lives
9/27/2017

This year is the 25th anniversary for Optos.  With such a significant milestone, it is customary to reflect on the journey. It all began when Douglas Anderson, our Founder set out to commercialize a patient-friendly product that encompassed a digital widefield image of the retina in a single capture. His young son, Leif was the impetus behind this mission. Whilst he had been receiving regular eye exams, the doctor was unable to examine Leif’s entire retina and he became blind in one eye when a peripheral retinal detachment went undetected. From that point on, the mission of saving sight and saving lives was engrained in the fabric of our culture and has become the cornerstone of our vision to be The Retina Company.

Interview with Douglas Anderson
9/25/2017

Douglas Anderson, the founder of Optos, reflects on a 25-year-long journey to bring ultra-widefield imaging into the consulting room, inspired by the experience of his own son. Interview conducted by Optician

Evaluation of coronary artery disease as a risk factor for reticular pseudodrusen
9/11/2017

Specific AMD features in UWF images were graded. Standardised grids were used to record the spatial location of AMD features, including RPD. We found no evidence to support an association between coronary artery disease and RPD. RPD was strongly associated with intermediate AMD features.  

Refining Coats' disease by ultra-widefield imaging and optical coherence tomography angiography
9/5/2017

Demonstrated that Coats' disease is a highly asymmetric bilateral disease and that UWF imaging is able to identify more retinal pathology than standard fundus imaging, thus guiding proper retinal photocoagulation. All clinically affected eyes exhibited retinal pathology at UWF imaging with the temporal sector most involved followed by the inferior, nasal, superior and macula.

US Ophthalmic Review Supplement
5/2/2017

The incidence of diabetes in the US population has increased more than fourfold over the last several decades and a high proportion of these patients manifest diabetic eye disease, including diabetic retinopathy (DR) and diabetic macular edema (DME). 

Advanced Ocular Care
4/1/2017

Advanced Ocular Care - Ultra-widefield Retinal Imaging Facilitates Integrated Eyecare

Retinal Physician
4/1/2017

A review of modalities for widefield angiography and their application for various pathologies

Retina Today - More Than Uveitis
2/1/2017

Case study – optomap images are featured in the diagnosis and treatment

Optometric Office - Detecting Changes in Diabetic Retinopathy Featuring Optos and California af
1/1/2017

Retinal imaging tools assist with detection, patient education and disease management.

Nikon and Verily Establish Strategic Alliance to Develop Machine Learning-enabled Solutions for Diabetes-related Eye Disease
12/26/2016

December 26, 2016 - Nikon Corporation (Kazuo Ushida, President, Tokyo; referred to below as “Nikon”) and its subsidiary Optos Plc (Robert Kennedy, CEO, United Kingdom; referred to below as “Optos”) today announced a strategic alliance with Verily Life Sciences LLC (Andy Conrad, CEO, United States; referred to below as “Verily”, formerly known as Google Life Sciences) in the field of machine learning-enabled retinal imaging.

Clinical trial study results for optomap® suggest that peripheral retinal lesions predict progression of diabetic retinopathy
8/31/2015

Prospective 4 year study shows significance of peripheral lesions in predicting 3 to nearly 5-fold increased risk of diabetic retinopathy progression and development of proliferative diabetic retinopathy, respectively.

Delisting and Cancellation of Trading
5/26/2015

Further to the announcement made by Nikon Corporation and Optos plc (Optos) on 22 May 2015 that the Scheme has become effective in accordance with its terms, pursuant to Listing Rules 5.2 and 5.3 and the subsequent publication of the relevant dealing notice by the Financial Conduct Authority, Optos confirms that trading in Optos Shares on the London Stock Exchange's main market for listed securities and the listing of Optos Shares on the Official List were cancelled with effect from 8.00 a.m. today (UK time).

Satisfaction of US Merger Control Condition
4/28/2015

The boards of Nikon Corporation ("Nikon") and Optos plc ("Optos") announce that the waiting period under the Hart Scott Rodino Antitrust Improvements Act 1976, as amended, for the acquisition of Optos has expired and, accordingly, the Condition at paragraph 2(a) of Part Three of the Scheme Document, which was posted to Optos Shareholders on 27 March 2015 (the "Scheme Document"), has been satisfied.

Austrian Merger Clearance
4/23/2015

The boards of Nikon Corporation ("Nikon") and Optos plc ("Optos") announce that the acquisition of Optos by Nikon obtained merger control clearance in Austria today and, accordingly, the Condition at paragraph 2(b) of Part Three of the Scheme Document, which was posted to Optos Shareholders on 27 March 2015 (the "Scheme Document"), has been satisfied.

Results of the Court Meeting and General Meeting
4/23/2015

On 27 February 2015, the boards of Optos Plc (Optos) and Nikon Corporation (Nikon) announced that they had reached agreement on the terms of a recommended cash offer pursuant to which Nikon will acquire all of the issued and to be issued share capital of Optos (the Transaction).

First shipments of California Devices commence
3/31/2015

LONDON, UK, 31 March 2015 – Optos plc (LSE: OPTS), the leading medical retinal imaging company, today announces it has commenced first shipments of California, the second device from its next generation ultra-widefield (UWF™) imaging platform. 

Posting Announcement
3/27/2015

On 27 February 2015, the boards of Optos Plc (Optos) and Nikon Corporation (Nikon) announced that they had reached agreement on the terms of a recommended cash offer pursuant to which Nikon will acquire all of the issued and to be issued share capital of Optos (the Transaction).

Optos wins Technology of the Year at UK PLC Awards
3/24/2015

LONDON, UK, 24 March 2015 – Optos plc (LSE: OPTS), the leading medical retinal imaging company, today announces it has been awarded the prestigious 2014 Technology of The Year Award at the UK PLC Awards in London. 

Offer for Optos
2/28/2015

The boards of directors of Nikon Corporation ("Nikon") and Optos Plc ("Optos") are pleased to announce that they have agreed the terms of a recommended cash offer to be made by Nikon for the entire issued and to be issued share capital of Optos.

Preliminary Results FY14
11/19/2014

LONDON, UK, 19 November 2014 – Optos plc (LSE: OPTS), the leading medical retinal imaging company, today announces its preliminary results for the financial year ended 30 September 2014 (“FY14”).  All figures are reported in US$, the Company’s reporting currency.

Optos unveils California, its next generation ultra-wide imaging device
10/20/2014

LONDON, UK, 20 October 2014 – Optos plc (LSE: OPTS), the leading medical retinal imaging company, is pleased to announce that California, the second device from its next generation ultra-widefield (UWF) imaging platform, was unveiled at the American Academy of Ophthalmology (AAO) meeting in Chicago on Saturday, 18 October, 2014. 

Pre-Close Trading Update
10/10/2014

LONDON, UK, 10 October 2014 – Optos plc (LSE: OPTS), the leading medical retinal imaging company, today provides a pre-close trading update for the financial year ended 30 September 2014 (“FY14”), ahead of the publication of its Preliminary Results on 19 November 2014. All figures, which are reported in US dollars (US$), are unaudited.

Optos in £10 million collaboration with NHS
10/6/2014

LONDON, UK, 6 October 2014 – Optos plc (LSE: OPTS), the leading medical retinal imaging company, today announces a £10 million collaboration with Scientists and Clinicians from NHS Greater Glasgow and Clyde, and the Universities of Kent and Strathclyde, for the development of a new imaging technology that could allow earlier detection of sight threatening eye disease. 

Interim Management Statement
7/17/2014

LONDON, UK, 17 July 2014 – Optos plc (LSE: OPTS), the leading medical retinal imaging company, today publishes its Interim Management Statement for the period from 1 October 2013 to today, including data for the three month period ended 30 June 2014, the third quarter of the Company's FY14 financial year, and nine months to 30 June 2014 (YTD14).  All figures are reported in US$ and are unaudited.

Daytona Ultra-widefield Imaging Device from Optos plc Wins “Best Technology” at the 2014 European Mediscience Awards
6/25/2014

LONDON, UK, 20 June 2014 - Optos plc (LSE: OPTS), a leading medical retinal imaging company, is pleased to announce that it’s Daytona ultra-widefield imaging (UWF) device has won “Best Technology” at the 2014 Mediscience Awards.

Interim Results for the six months to 31 March 2014
5/14/2014

LONDON, UK, 15 May 2014 – Optos plc (LSE: OPTS), a leading medical retinal imaging company, today publishes its interim results for the first half of its financial year ending 30 September 2014 (H1 FY14).  All figures are reported in US$ and are unaudited.

Continued growth in new customers
1/21/2014

LONDON, UK, 21 January 2014 – Optos plc (LSE: OPTS), the leading medical retinal imaging company, today publishes its Interim Management Statement for the period from 1 October 2013 to today, including data for the three month period ended 31 December 2013, the first quarter of the Company's FY14 financial year.  All figures are reported in US$ and are unaudited.

Preliminary Results FY13
11/21/2013

LONDON, UK, 21 November 2013 – Optos plc (LSE: OPTS), the leading medical retinal imaging company, today announces its preliminary results for the year ended 30 September 2013 ("FY13").  All figures are reported in US$, the Company's reporting currency.

Rob Kennedy Appointed CFO
10/16/2013

LONDON, UK, 16 October 2013 – Optos plc (LSE: OPTS), a leading medical retinal imaging company, announces that Rob Kennedy, currently Interim CFO has been appointed CFO with immediate effect. Rob succeeds Louisa Burdett, whose decision to step down was announced in July.

Optos Secures First Corporate Account Order for Daytona in United States
10/9/2013

LONDON, UK, 9 October 2013 – Optos plc (LSE: OPTS), a leading medical retinal imaging company, announces that it has agreed terms to supply 100 Daytona ultra-widefield retinal imaging devices to HVHC, Inc. for installation in its Visionworks’ optometry stores in the USA.

Pre-Close Trading Update
10/9/2013

LONDON, UK, 9 October 2013 – Optos plc (LSE: OPTS), the leading medical retinal imaging company, today provides a pre-close trading update for the financial year ended 30 September 2013 (“FY13”), ahead of the publication of its Preliminary Results on 21 November 2013. All figures, which are reported in US dollars (US$), are unaudited.

Directorate Change
7/18/2013

LONDON, UK, 18 July 2013 – Optos plc (LSE: OPTS), the leading medical retinal imaging company, today announces that Louisa Burdett has decided to step down from her role as Chief Financial Officer. Robert Kennedy, currently Group Director of Finance and Company Secretary, will become interim CFO with immediate effect. Louisa will remain with the business until the end of September to facilitate an orderly handover of responsibilities.

Interim Management Statement
7/18/2013

LONDON, UK, 18 July 2013 – Optos plc (LSE: OPTS), the leading medical retinal imaging company, today publishes its Interim Management Statement for the period from 1st October 2012 to today, including data for the third quarter of its financial year ending 30 September 2013 (Q313) and nine months to 30 June 2013 (YTD13). All figures are reported in US$ and are unaudited.

Interim Results for the six months to 31st March 2013 Transitioning in FY13 from renewals to new customers
5/16/2013

LONDON, UK, 16th May 2013 – Optos plc (LSE: OPTS), a leading medical retinal imaging company, today publishes its interim results for the first half of its financial year ending 30 September 2013 (H1 FY13).  All figures are reported in US$ and are unaudited.

optomap Increases Percentage of Pathology Detected in Conventional Eye Exam
4/15/2013

April 15, 2013, MARLBOROUGH, MA Optos plc (LSE: OPTS), a world leader in retinal imaging, today announced that the results from a study comparing retinal imaging techniques in 339 eyes conducted at the New England College of Optometry were published in Eye and Brain 1.

Optos plc provides an update on current trading and further details of the sale of 250 Daytona devices to OPSM
3/20/2013

LONDON, UK, 20th March 2013 – Optos plc (LSE: OPTS), a leading medical retinal imaging company, provides an update on current trading in advance of its interim results announcement on 16th May 2013.

OptosOCT/SLO – Retinal Structure and Functional Testing in one Device
3/11/2013

11 March 2013 - Optos plc (LSE: OPTS), a world leader in retinal imaging, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Microperimetry as part of the OptosOCT SLO. Microperimetry assesses retinal sensitivity providing a precise correlation between structural pathology and corresponding visual functional defects. This data provides more clinical information to support the evaluation of patients’ vision.

Interim Management Statement
1/22/2013

LONDON, UK, 22 January 2013 – Optos plc (LSE: OPTS), the leading medical retinal imaging company, today publishes its Interim Management Statement. All financial figures are in US$ and cover the three month period ended 31st December 2012, the first quarter of the company's FY13 financial year. All figures are unaudited.

Preliminary Results FY12
11/21/2012

LONDON, UK, 21 November 2012 – Optos plc (LSE: OPTS), the leading medical retinal imaging company, today announces its preliminary results for the year ended 30 September 2012. The results are denominated in $US, the Company's reporting currency.